case_images: PMC11179442_01
case_images: Before treatment with upadacitinib.
case_images: 10.1177_2050313X241260497-fig1.jpg
case_images: PMC11179442_01_10.1177_2050313X241260497-fig1.jpg
case_images: fig1-2050313X241260497
case_images: His severity scoring was recorded as body surface area (BSA) of 95%, eczema area and severity index (EASI) 72, IGA 4 (Figure 1).
case_images: One month of treatment with upadacitinib.
case_images: 10.1177_2050313X241260497-fig2.jpg
case_images: PMC11179442_01_10.1177_2050313X241260497-fig2.jpg
case_images: fig2-2050313X241260497
case_images: After only less than 1 month of treatment with upadacitinib, the patient's skin improved to BSA 25% and he was able to resume work, sleep, and other activities of daily living (Figure 2).